Skip to main content
Contact Us
Subscribe
E-Edition
77°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Puma Biotechnology, Inc.
< Previous
1
2
3
Next >
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
March 05, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference
February 26, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
February 13, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
December 23, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
November 20, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Third Quarter 2024 Financial Results
November 07, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
October 24, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Second Quarter Financial Results
August 01, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
July 18, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
June 03, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
June 02, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Join Russell 3000 Index
May 28, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
May 23, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports First Quarter Financial Results
May 02, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
April 18, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
March 20, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
February 29, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 27, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
February 22, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Tickers
PBYI
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.